Related Experiment Video
Updated: Feb 5, 2026
05:54
MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
Published on: December 13, 2017
14.9K
A Patient Centricity Team Tool to Enable Patient-Focused Drug Development
Rebecca Ashkenazy1, Roslyn F Schneider2
11 US Medical Affairs, Women's and Men's Health Lead, Global Established Pharma, Pfizer Inc, New York, NY, USA.
Therapeutic Innovation & Regulatory Science
|September 21, 2018
Summary
A new Patient Centricity Team Tool (PCTT) was piloted to assess patient-focused drug development efforts. Initial results show varied team activities, highlighting the need for further validation to guide improvements.
Area of Science:
- Pharmaceutical Sciences
- Patient Advocacy
- Drug Development
Background:
- Patient-focused drug development is crucial for therapeutic success.
- Assessing patient centricity within pharmaceutical teams is challenging.
- A standardized tool is needed to evaluate patient engagement in drug development.
Purpose of the Study:
- To develop and pilot a Patient Centricity Team Tool (PCTT) for assessing patient-focused drug development.
- To evaluate the frequency of patient centricity efforts across different team dimensions.
- To identify areas for improvement in patient engagement within pharmaceutical organizations.
Main Methods:
- A multifunctional patient affairs team developed a computer-based survey tool (PCTT).
- The PCTT interrogates team efforts in 20 areas across 4 dimensions: people, purpose, process, and actions.
- A pilot study was conducted with a Phase III product team.
Main Results:
- The pilot indicated a spectrum of team activity frequencies related to patient-focused drug development.
- Results varied, reflecting the specific team, product, and lifecycle stage.
- The tool's current lack of validation limits diagnostic interpretation of activities.
Conclusions:
- The PCTT shows potential for assessing patient centricity in drug development.
- Further validation and broader implementation are needed for robust interpretation.
- Long-term use may lead to organizational, product, and patient benefits.
Keywords:
development strategypatient centricitypatient voicepatient-focused drug developmentteam assessmentMore Related Videos
Related Concept Videos
01:15Drug Dosing: Geriatric Patients
274
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
274
01:21Drug Dosing: Obese Patients
265
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
265
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
264
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
264
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
311
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
311
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
233
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
233
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
327
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
327